Past issues are only available to subscribers. If you are not a member, click here to join.

June 2016PDF



Leukemia and Lymphoma

Three Phase III Studies of Imbruvica Presented at ASCO Annual Meeting

AbbVie published longer-term follow-up results from three phase III studies of Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma: RESONATE, RESONATE-2 and HELIOS.

These data were presented at the annual meeting of the American Society of Clinical Oncology. Imbruvica is jointly developed and commercialized in the U.S. by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech Inc.

“Our clinical data presented at this year’s ASCO from several randomized studies demonstrate solid durability of response with Imbruvica in patients with CLL/SLL with additional follow-up of up to three years,” said Danelle James, head of oncology at Pharmacyclics.



Breast Cancer

Combination of Surgery and Standard Therapy Increases Survival in Stage IV, Study Says

A combination of surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by standard therapies, can add months to patients’ lives when compared with standard therapy alone, according to an international phase III study.

“Our findings will change the standard of care for women newly diagnosed with stage IV breast cancer,” said lead investigator Atilla Soran, clinical professor of surgery at the University of Pittsburgh School of Medicine and breast surgical oncologist with UPMC CancerCenter. “We’ve shown that surgery to remove the primary tumor—either through lumpectomy or mastectomy—followed by standard therapy, is beneficial over no surgery.”



Drugs and Targets

FDA Approves EGFR Companion Diagnostic For Tarceva Therapy




Soft Tissue Sarcoma

Phase III Eribulin Trial Boosts OS in Liposarcoma Patients


Multiple Myeloma

Kyprolis, Lenalidomide and Dexamethasone Combination Improves PFS, OS in Phase III


NCI CTEP-Approved Trials for the Month of June

- Jun. 30, 2016
Issue 25 - Jun. 24, 2016
  • Stanford, Intermountain and Providence Use Syapse Platform to Integrate Their Data

    Three health systems—Stanford Cancer Institute, Intermountain Healthcare and Providence Health and Services—have agreed to eliminate the electronic barriers between their medical records, tumor registries and genomics databases.

    The three entities said they have started to use a common IT platform to achieve interoperability and guide clinical decision-making.

    That platform is Syapse, a startup that is emerging as an important player in the ongoing conversation on bioinformatics and data sharing in oncology, led by Vice President Joe Biden and the National Cancer Moonshot Initiative.

    • Related Coverage of the Cancer Moonshot

  • Conversation with The Cancer Letter

    Hirsch: I Dropped Out of Stanford to Start Syapse

    Jonathan Hirsch was studying neuroscience at Stanford University when he wandered into two oncology classes and saw an opportunity to change the way health systems handle genomic data.

    “I started getting really immersed in molecular oncology, and the challenges in implementing molecularly guided treatment started coming together with the challenges in utilizing complex data,” Hirsch said to The Cancer Letter.

  • Joint BSA-NCAB Meeting

    The Moonshot’s Metric for Success: Avoiding a Single, Tangible Endpoint

    How will the success of the moonshot be measured? NCI Acting Director Doug Lowy touched on the subject during the joint meeting of the institute’s Board of Scientific Advisors and the National Cancer Advisory Board June 21.

    The moonshots of the 1960s were essentially engineering problems that had tangible goals. Cancer is an evolutionary problem, and the stated goal of the moonshot in cancer research, led by Vice President Joe Biden, is perhaps deliberately vague: to achieve a decade’s worth of progress in just five years.

    “Has there been any discussion of an endpoint that you can point to—like planting the flag on the moon, or sequencing the three-billionth base pair of the genome project?” asked BSA member Lincoln Stein, director of the Informatics and BioComputing Platform at the Ontario Institute for Cancer Research, during the meeting. “Something that looks like an achievable endpoint?”

  • Funding Opportunity

    SU2C, Merck Taking Proposals for Keytruda

    Stand Up To Cancer announced a request for proposals under SU2C Catalyst, a program supporting clinical trials and translational research.

  • In Brief

    • NCI Surgery Branch resumes enrollment in immunotherapy trials
    • Rajesh Garg named president and CEO of Cancer Treatment Centers of America
    • Prostate Cancer Foundation names 24 Young Investigator Award winners
    • Shuanzeng “Sam” Wei and Phillip Pancari join Fox Chase
    • MIT’s Tyler Jacks, Susan Hockfield, and Phillip Sharp publish report on convergence
    • Pancreatic Cancer Action Network lobbies Congress for research funding
    • Leukemia and Lymphoma Society and the American Society of Hematology to collaborate on promoting AML treatment research
Issue 24 - Jun. 17, 2016
  • Moonshot May Play Role in $400 Million Annual Contract to Run NCI’s Frederick Lab

    The contract for operations and technical support at the Frederick National Laboratory for Cancer Research could be accepting proposals as early as next month—but NCI advisors said they are hoping to slow the recompetition process to reform the laboratory’s mission.

    Moreover, NCI should consider how the laboratory could contribute to Vice President Joe Biden’s National Cancer Moonshot Initiative, members of the Frederick National Laboratory Advisory Committee said at a recent meeting.

  • Task Force Adds Tests to Colon Screening Guideline

    The final version of guidelines for colorectal cancer screening by the U.S. Preventive Services Task Force differ substantively from the group’s draft version published last October.

    The final version—unlike the draft—lists CT colonography and FIT-DNA as screening methods that are equal to others.

    It’s unclear whether political pressure had any role in prompting the panel to broaden its list of detection strategies from three to seven in the past six months.

  • Conversation with The Cancer Letter

    Guideline Edits Rooted in Science, Former USPSTF Member Says

    “I don’t see this recommendation as differing in any substantial way from some others that we’ve made, where we suggested that patients talk with their clinicians, and the important messages here is that colorectal cancer screening works, that colorectal cancer screening reduces deaths from colorectal cancer,” said Douglas Owens, a who has rotated off the U.S. Preventive Services Task Force, and was involved in developing the colorectal cancer screening guideline published earlier this week.

  • In Brief

    • President Obama names six appointees to the NCAB
    • Stand Up to Cancer to host fifth-biennial televised fundraiser
    • Kety Duron joins City of Hope as chief human resources officer
    • Miami Cancer Institute takes delivery of 220-ton proton therapy cyclotron
    • Takeda and M2Gen to collaborate on ORIEN genomic data
    • Mayo Clinic and Kiyatec to collaborate on ovarian cancer care
    • St. Jude receives pathology accreditation through College of American Pathologists
  • Drugs and Targets

    • Canadian review agency delivers positive opinion for Opdivo in NSCLC
    • Genomic Health launches Oncotype SEQ Liquid Select biopsy test